Industry

Regeneron Secures FDA Approval to Extend Eylea HD Dosing Intervals to Up to 20 Weeks

Eyewire+5h ago2 min read

The FDA has approved extended dosing intervals of up to every 20 weeks for Eylea HD (aflibercept) in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The expanded dosing schedule applies to patients who have demonstrated a successful response after 1 year of treatment, based on visual and anatomical outcomes, according to Regeneron. The approval allows some patients to receive as few as two to three injections per year. Alongside the dosing update, the FDA has revised the Eylea HD label to include 96-week (2-year) results from the pivotal PULSAR trial in wet AMD and PHOTON trial in DME, both of which demonstrated sustained efficacy and safety with extended dosing intervals. “The potential for needing only 2 or 3 Eylea HD injections a year to manage certain retinal diseases is an exciting advance,” said Dr. Michael A. Klufas of Wills Eye Hospital Retina Service. “With the extended dosing schedule and compelling 2-year data, I have greater confidence that patients can maintain visual and anatomical improvements long term with a safety profile comparable to Eylea 2 mg.” With the latest approval, Eylea HD offers a highly flexible treatment approach. Patients may be treated as frequently as every 4 weeks or as infrequently as every 20 weeks, depending on individual response and physician assessment. This represents the widest range of dosing intervals among approved injectable anti-VEGF therapies. The updated label includes detailed findings from patients who completed 96 weeks in the trials (PULSAR n=583; PHOTON n=395). Results showed that most patients maintained or extended their dosing intervals while preserving the gains achieved in the first year. In wet AMD, 71% and 47% of patients reached dosing intervals of at least 16 weeks and 20 weeks, respectively. In DME, 72% and 44% achieved those same intervals. “We have once again raised the bar,” said George D. Yancopoulos, MD, PhD, Regeneron’s Board co-Chair, President, and Chief Scientific Officer. “Eylea HD is the first and only injectable anti-VEGF therapy that enables treatment as infrequently as every 5 months for appropriate patients, significantly reducing treatment burden while maintaining efficacy.” The most commonly reported adverse reactions (≥3%) included cataract, conjunctival hemorrhage, corneal epithelium defects, increased IOP, ocular discomfort, retinal hemorrhage, blurred vision, vitreous detachment, and floaters. Looking ahead, the FDA is also reviewing a prefilled syringe version of Eylea HD, with a target action date set for April 2026 under a supplemental application.

Read full article on Eyewire+

AI Summary

Quick Take

The FDA has approved extended dosing intervals of up to 20 weeks for Eylea HD (aflibercept 8mg) in patients with wet AMD and DME who demonstrate a successful response after one year of treatment. This update allows for as few as two to three injections annually, with clinical data showing that nearly half of patients in pivotal trials maintained 20-week intervals through two years of treatment.

Why It Matters

Reducing treatment burden remains the primary goal in retinal therapy, as frequent injections are a major driver of patient non-compliance and subsequent vision loss in real-world settings. By extending the interval to five months, Eylea HD now offers the longest approved dosing window among anti-VEGF agents, providing a significant competitive advantage against other high-durability therapies. This flexibility allows clinicians to highly individualize care, potentially maintaining anatomical gains with significantly fewer office visits for stable patients.

Key Findings

In the PULSAR trial for wet AMD, 71% of patients maintained dosing intervals of at least 16 weeks, and 47% reached 20-week intervals by the end of 96 weeks.
In the PHOTON trial for DME, 72% of patients achieved intervals of 16 weeks or longer, while 44% successfully extended to 20-week dosing.
The updated FDA label now incorporates 96-week (2-year) data, confirming that most patients preserved the visual and anatomical gains achieved in the first year.
Eylea HD provides the widest range of dosing flexibility among approved anti-VEGFs, with intervals ranging from every 4 weeks to every 20 weeks.
The safety profile remains comparable to Eylea 2 mg, with common adverse reactions (≥3%) including cataract, conjunctival hemorrhage, and increased intraocular pressure.

Study Snapshot

Design

Two pivotal Phase 3 randomized trials (PULSAR and PHOTON)

Population

Patients with wet age-related macular degeneration and diabetic macular edema

Sample Size

978 patients (583 in PULSAR; 395 in PHOTON)

Practice Implications

Clinicians can now consider extending stable Eylea HD patients to a 20-week interval after the first year of treatment, provided they meet visual and anatomical criteria. This shift may require a recalibration of monitoring schedules and patient counseling regarding the long-term durability of the 8mg dose. It is particularly relevant for patients who are well-controlled but burdened by the logistics of frequent injections.

Who's Affected

Retina SpecialistsOphthalmologistsPractice Owners

What's Next

The FDA is currently reviewing a supplemental application for a prefilled syringe (PFS) version of Eylea HD. The target action date for this regulatory decision is set for April 2026, which would further streamline the administration process in high-volume clinics.

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.